Consumer Staples • Retail-Drug Stores and Proprietary Stores
$1.18 ▼ -0.01
(-0.84%)
MKT CAP: $25.6M • VOL: 12.5K
52W L $1 52W H $4
PETS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-31 | FY 2024
FILED 2025-03-31 | FY 2023
FILED 2024-03-31 |
|---|---|---|---|
| Revenue (Total Sales) | $179.0M | $227.0M | $274.1M |
| YoY Revenue Growth % | -21.1% | -17.2% | — |
| Gross Profit | $50.2M | $69.1M | — |
| Gross Margin % | 28.1% | 30.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$58.7M | -$1.5M | -$8.2M |
| Operating Margin % | -32.8% | -0.7% | -3.0% |
| Net Income (GAAP) | -$57.3M | -$6.3M | -$7.5M |
| EBITDA (Normalized) | -$55.0M | $2.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$28.4M | $4.7M | $4.3M |
| Capital Expenditures (CapEx) | $4.6M | $5.1M | — |
| Free Cash Flow (FCF) | -$33.0M | -$395.0K | $4.3M |
| FCF Margin % | -18.4% | -0.2% | 1.6% |
| Return on Invested Capital (ROIC %) | -45.0% | -2.6% | — |
| Cash & Short-Term Equivalents | $26.9M | $50.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $32.8M | $96.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PETS.